Recent Finacing
Recent Raise
Therabron Therapeutics develops recombinant human CC10 (rhCC10) secretoglobin therapeutics, advancing lead candidate CG100 in Phase 2 for bronchopulmonary dysplasia in preterm infants and moving respiratory programs toward clinical trials.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors